

25th July, 2025

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the Press Release dated 25th July, 2025.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Cipla Limited**




Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Chirag Hotchandani

Q1 FY26 Results

Profitability Momentum Continues with Strong EBITDA Margin at 25.6%

	Income from Operations	EBITDA	PAT
Q1 FY26:	INR 6,957 Cr  4% YoY	INR 1,778 Cr (25.6%)  4% YoY	INR 1,298 Cr (18.7%)  10% YoY

Mumbai, July 25, 2025: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended June 30th, 2025.

Key highlights for the quarter

- **One-India:** One India Business delivered a growth of 6% YoY for the quarter, breaching the threshold of INR 3,000 Cr for the first time ever in the opening quarter of any financial year.
- **North America:** Delivered quarterly revenue of \$ 226 Mn supported by traction in differentiated assets. Launched Nano Paclitaxel vials (ANDA) and Nilotinib Capsules (NDA).
- **One Africa:** Growth momentum continued with overall revenue growth at 11% YoY in USD terms. Prescription business ranked No. 2 in the market*.
- **Emerging Markets and Europe:** Posted a healthy revenue growth of 8% YoY in USD terms.
- **R&D investments:** Stood at INR 432 Cr or 6.2% of sales, driven by product filings and development efforts.
- **Strong net cash:** Net cash position of INR 10,379 Cr; Debt primarily includes lease liabilities and working capital requirements.

*Market data as per IQVIA MAT May'2025

"I am pleased to share that we continue to make considerable progress across our focused markets. In Q1FY26, we delivered steady revenue of INR 6,957 Cr, with a healthy EBITDA margin of 25.6%. What makes this performance commendable is that it builds on a strong prior-year quarter, where we achieved our highest-ever US Generics revenue. Our One-India business grew at a 6% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics recorded a strong growth and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of \$ 226 Mn. In One Africa, we achieved a solid growth of 11% YoY in USD terms. Emerging Markets and Europe delivered a healthy revenue growth of 8% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front".

Umang Vohra
MD and Global CEO, Cipla Ltd

For Queries Contact:

Corporate Communications
Heena Kanal
CorpComm@cipla.com

Investor Relations
Diksha Maheshwari
Investor.Relations@cipla.com

Cipla Ltd.
Cipla House,
Peninsula Business Park,
Ganpatrao Kadam Marg,
Lower Parel, Mumbai-400013

Market Updates

❖ One India Business

Branded Prescription:

Key therapies like Respiratory, Urology, Cardiac, Anti-diabetes and Anti-infectives grew faster than the market, with the overall chronic mix at 61.5% as per IQVIA MAT Jun'25. Successfully launched Voltido Trio, flagship addition to the Respiratory portfolio.

Trade Generics:

The business recorded a strong growth, and the performance was supported by execution excellence in key therapies, new introductions and technological interventions. The business launched 7 new products in Q1 FY26, including entry into Orthopaedics to expand therapy coverage.

Consumer Health:

Anchor brands of Nicotex, Omnigel and Cipladine maintained leadership positions in their respective market segments.

❖ North America

North America business delivered a quarterly revenue of \$ 226 Mn, driven by the performance of differentiated assets. Albuterol ranked No.1 in the overall U.S. Albuterol MDI market, with a 19.5% market* share. Lanreotide also performed well, reaching a 21% market share** during the quarter. The launch of Nano Paclitaxel vials (ANDA) and Nilotinib Capsules (NDA) is likely to further strengthen the business position in complex generics and Oncology. Additionally, Cipla entered into a strategic agreement to launch its first biosimilar in the U.S., with commercialization expected in Q2 FY26.

❖ One Africa

One Africa recorded a strong growth of 11% YoY in USD terms. In Private Market, secondary growth was at a healthy 5.6% versus the market** growth of 3.8%. South Africa overall private market ranked No. 3 in the market with the prescription business maintaining its No.2 position. This growth was propelled by uptick in key therapies, tender business as well as new launches.

❖ Emerging Markets and Europe

Deep market focus strategy in Emerging Markets and Europe has laid a solid foundation, with the business delivering a growth of 8% in USD terms with uptick in both DTM and B2B categories, along with sustained overall margins.

QUARTERLY BUSINESS WISE SALES PERFORMANCE

Business (In INR Cr)	Q1FY26	Q1FY25	Y-o-Y Growth
India (Rx + Gx + CHL [^])	3,070	2,898	6%
North America	1,933	2,087	-7%
One Africa [#]	871	766	14%
South Africa	695	626	11%
Emerging Markets and Europe	861	779	11%
API	102	98	3%
Others	121	65	85%
Total	6,957	6,694	4%

[^] CHL – Cipla Health limited | [#] Includes South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access

CONSOLIDATED PROFIT & LOSS STATEMENT

In INR Cr	Q1FY26	Q1FY25	Y-o-Y Growth
Total Income from Operations	6,957	6,694	3.9%
EBITDA	1,778	1,716	3.6%
% of Income from Operations	25.6%	25.6%	-7 bps
PAT	1,298	1,178	10.2%

BALANCE SHEET

Key Balance Sheet Items (INR Cr)	Jun-25	Jun-24
Equity	32,665	28,058
Total Debt [#]	459	547
Inventory	6,091	5,531
Cash and Cash Equivalents*	10,838	8,996
Trade Receivables	6,254	4,989
Trade Payables	3,093	2,742
Net Tangible Assets	6,669	6,210
Goodwill and Intangibles	5,138	4,941

[#]Total debt includes lease liabilities and working capital loan | ^{*}Cash and Cash Equivalents include Cash and Bank Balances, Current Investments and Fixed Deposits

Announcement

Cipla to release Q1FY26 unaudited Financial Results on July 25, 2025

Date: July 25, 2025

- **1500 hrs IST – EARNINGS CONFERENCE CALL**

The Company will host an earnings conference call at 1500 hrs IST (1730 hrs SST/HKT, 1030 hrs BST, 0530 hrs US ET), during which the leadership team will discuss financial performance and take questions. A transcript of the conference call will be available at www.cipla.com.

Earnings Conference Call Dial-in Information

Date and Time	July 25, 2025 at 1500 – 1600 hrs IST 1730 – 1830 hrs SST/HKT 1030 – 1130 hrs BST 0530 – 0630 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: (+91 22 6280 1562) (+91 22 7115 8387)
Diamond pass link	Click here to register
Toll Free Number	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

ABOUT CIPLA LTD

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Jun'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT May'25), and 3rd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT May'25). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Disclaimer: Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.